CAS:571190-30-2

(Synonyms PD 0332991)

571190-30-2 Technical Data:

Price and Availability of Cas No:571190-30-2

Cas : 571190-30-2 M.Wt: 447.5327
Cas : 571190-30-2 Formula: C24H29N7O2
Cas : 571190-30-2 Purity: >98 %
Cas : 571190-30-2 Storage: at 20℃ 2 years
Cas : 571190-30-2 Solubility: DMSO: 0.2 mg/mL (Need ultrasonic or warming)
Cas : 571190-30-2 Name: Palbociclib

USD
1g/$395	In-stock
5mg/$50	In-stock
10mg/$70	In-stock
50mg/$90	In-stock
100mg/$110	In-stock
200mg/$140	In-stock
500mg/$260	In-stock
1g	Get quote
5g	Get quote
>10g	Get quote
We match the lowest price on market.
We offer a substantial discount on larger orders,please inquire via sales@chemexpress.cn or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Online Inquiry

Inquiry Online

Hide

Salutation:		Country:
Customer:		Company Name:
Email:		Requested quantity:
Remarks:

571190-30-2 Data Sheet:

Introduction of 571190-30-2 :
Palbociclib is a highly specific inhibitor of Cdk4 (IC₅₀=11 nM) and Cdk6 (IC₅₀=16 nM), having no activity against a panel of 36 additional protein kinases. IC50 & Target: IC50: 11 nM (Cdk4), 16 nM (Cdk6)^[1] In Vitro: The IC₅₀ of Palbociclib (PD 0332991) for reduction of retinoblastoma (Rb) phosphorylation at Ser⁷⁸⁰ in MDA-MB-435 breast carcinoma cells is 66 nM. Palbociclib is equally effective at reducing Rb phosphorylation at Ser⁷⁹⁵ in this tumor with an IC₅₀ of 63 nM, and similar effects on both Ser⁷⁸⁰ and Ser⁷⁹⁵ phosphorylation are obtained in the Colo-205 colon carcinoma^[1]. The MP-MRT-AN (AN), KP-MRT-RY (RY), G401, and KP-MRT-NS (NS) cell lines are effectively inhibited by Palbociclib (PD) in a concentration-dependent manner in a WST-8 assay. The IC₅₀s are 0.01 ?M, 0.01 ?M, 0.06 ?M, and 0.6 ?M, respectively. In contrast, the KP-MRT-YM (YM) cell line is resistant to Palbociclib (IC₅₀>10 ?M). The flow cytometry results show that Palbociclib at concentrations between 0 to 1.0 ?M induces G1 arrest in the AN, RY, G401 and NS cell lines in a concentration-dependent manner, but has no effect on YM cells. The BrdU incorporation results are consistent with the WST-8 and flow cytometry results: PD reduces BrdU incorporation (indicating G1 arrest) in the AN, RY, G401 and NS cell lines, but not in the YM cell line. Palbociclib, even at a concentration of 0.05 ?M, significantly reduces BrdU incorporation in the AN, RY, and G401 cell lines (p<0.05)^[2]. In Vivo: Palbociclib (PD 0332991) exhibits significant antitumor efficacy against multiple human tumor xenograft models. In mice bearing Colo-205 colon carcinoma xenografts (p16 deleted), daily p.o. dosing for 14 days with Palbociclib (150 or 75 mg/kg) produces rapid tumor regressions and a corresponding tumor growth delay of ~50 days with >1 log of tumor cell kill at the highest dose tested. At 37.5 mg/kg, the tumor slowly regressed during treatment. Even at doses as low as 12.5 mg/kg, a 13-day growth delay is obtained indicating a 90% inhibition of tumor growth rate. Likewise, robust antitumor activity is seen in the MDA-MB-435 breast carcinoma (p16 deleted) where complete tumor stasis is apparent at 150 mg/kg and some cell kill is evident at the highest dose^[1].

References on 571190-30-2 :

Insert title here

Products are for research use only. Not for human use. We do not sell to patients. Copyright © 2009 Haoyuan Chemexpress All Rights Reserved
ADDRESS: 6/F, No. 2 Building, No. 720,Cailun Road, Shanghai, P.R.China
TEL: 86-21-58998590 FAX: 86-21-53700326, 86-21-58998590 E-mail： sales@chemexpress.cn